( 2.2 2.3 C...)Ferring Reports on ENDOMETRIN Presentations at Pacific Coast,Reproductive Society Annual Meeting,Health

2.2 2.3 Clinical intrauterine pregnancy (per cycle) 20 (50.0%) 103 (51.5%) 1st trimester pregnancy loss 0 (0.0%) 6 (5.8%) 2nd trimester pregnancy loss 1 (5.0%) 3 (2.9%) Live birth (per cycle) 19 (47.5%) 94 (47.0%)

About Luteal Support

Successful implantation of the embryo depends on adequate preparation of the endometrium, the mucous membrane lining the uterus. The corpus luteum, formed after the oocyte is released, secretes progesterone to induce secretory transformation of the endometrium. Since natural progesterone production may be compromised by in vitro fertilization (IVF), progesterone supplementation is believed to be necessary to provide the proper support for implantation and the early stages of pregnancy. Studies have shown that luteal support with progesterone after an assisted reproductive technology (ART) can result in increased pregnancy rates.

Currently available progesterone supplements come in oral, intramuscular (IM) injection, vaginal gel and suppository forms.

About BRAVELLE and MENOPUR

BRAVELLE(R) (urofollitropin for injection, purified) and MENOPUR (R) (menotropins for injection, USP), like all gonadotropins, are potent substances capable of causing mild to severe adverse reactions, including OHSS (incidence of 6.0% and 3.8%, respectively), with or without pulmonary or vascular complications, in women undergoing therapy for infertility.

The treatments are marketed by Ferring Pharmaceuticals Inc., a world leader in naturally occurring protein hormones. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe these medications. Like other products for ovarian stimulation, treatment with BRAVELLE(R) and/or MENOPUR(R) may result in multiple gestations.

Ab
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia